The estimated Net Worth of Mostafa Ronaghi is at least $16.2 Milione dollars as of 10 December 2020. Mostafa Ronaghi owns over 5,000 units of Illumina Inc stock worth over $10,006,622 and over the last 16 years he sold ILMN stock worth over $2,656,470. In addition, he makes $3,541,310 as Senior Vice President of Entrepreneurial Development at Illumina Inc.
Mostafa has made over 38 trades of the Illumina Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of ILMN stock worth $1,692,900 on 10 December 2020.
The largest trade he's ever made was exercising 59,000 units of Illumina Inc stock on 23 April 2013 worth over $2,423,130. On average, Mostafa trades about 5,729 units every 35 days since 2008. As of 10 December 2020 he still owns at least 80,162 units of Illumina Inc stock.
You can see the complete history of Mostafa Ronaghi stock trades at the bottom of the page.
Dr. Mostafa Ronaghi Ph.D. serves as Senior Vice President of Entrepreneurial Development of the Company. Dr. Ronaghi joined Illumina in August 2008; 2002 – 2008: principal investigator at Stanford University, where Dr. Ronaghi focused on the development of novel tools for molecular diagnostic applications; 2007 – 2008: chairman and chief scientific officer for Avantome, Inc. a privately-held sequencing company co-founded by Dr. Ronaghi and acquired by Illumina in 2008.
As the Senior Vice President of Entrepreneurial Development of Illumina Inc, the total compensation of Mostafa Ronaghi at Illumina Inc is $3,541,310. There are no executives at Illumina Inc getting paid more.
Mostafa Ronaghi is 50, he's been the Senior Vice President of Entrepreneurial Development of Illumina Inc since 2020. There are 14 older and 6 younger executives at Illumina Inc. The oldest executive at Illumina Inc is John Thompson, 71, who is the Lead Independent Director.
Mostafa's mailing address filed with the SEC is C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley e Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: